thomsen-friedenreich antigen has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anthony, DC; Glinskii, OV; Glinsky, GV; Glinsky, VV; Mawhinney, TP; Mossine, VV; Pienta, KJ; Sud, S | 1 |
| Igawa, M; Moriyama, H; Nakano, H; Nihira, H | 1 |
2 other study(ies) available for thomsen-friedenreich antigen and Bone Cancer
| Article | Year |
|---|---|
Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomimetic Materials; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Galectin 3; Humans; Lactulose; Leucine; Male; Mice; Mice, SCID; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
T antigen expression in benign hyperplasia and adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Bone Neoplasms; Disaccharides; Histocytochemistry; Humans; Immunoenzyme Techniques; Lectins; Male; MNSs Blood-Group System; Peanut Agglutinin; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms | 1987 |